To investigate the effects of ultrasound-guided percutaneous cryoablation combined with modified Buzhong Yiqi Decoction (补中益气汤) and Guizhi Fuling Pills (桂枝茯苓丸) on serum total prostate-specific antigen (tPSA), free prostate-specific antigen (F-PSA) and vascular endothelial growth factor (VEGF) in patients with prostate cancer.

A total of 110 prostate cancer patients with qi stagnation and blood stasis syndrome admitted to our hospital from February 2022 to January 2023 were retrospectively enrolled and divided into control group and study group with 55 cases in each group according to odd and even admission numbers. The control group received ultrasound-guided percutaneous cryoablation alone, while the study group was treated with oral modified Buzhong Yiqi Decoction and Guizhi Fuling Pills for 3 months on the basis of cryoablation. Fasting venous blood was collected before treatment and at 1, 3 and 9 months after treatment. ELISA were used to detect serum tPSA, F-PSA and VEGF levels, and TCM syndrome scores were evaluated simultaneously.

There were no significant differences in serum tPSA, F-PSA and VEGF between the two groups before treatment (P>0.05). No intergroup differences of the three indexes were observed at 1 and 3 months after treatment (P>0.05). At 9 months after treatment, the serum tPSA and F-PSA levels of the study group were lower than those of the control group, and the TCM syndrome scores were significantly improved (all P<0.05). There was no statistical difference in VEGF levels between the two groups at all followup time points (P>0.05).

Ultrasound-guided percutaneous cryoablation combined with modified Buzhong Yiqi Decoction and Guizhi Fuling Pills can effectively reduce long-term serum tPSA and F-PSA levels and improve TCM syndromes in prostate cancer patients, while it has no obvious regulatory effect on serum VEGF.